First Republic Investment Management Inc. Raises Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)
First Republic Investment Management Inc. Raises Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)
First Republic Investment Management Inc. boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 17.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 15,000 shares of the biotechnology company's stock after buying an additional 2,215 shares during the period. First Republic Investment Management Inc.'s holdings in Ascendis Pharma A/S were worth $1,549,000 as of its most recent SEC filing.
第一共和投資管理公司(First Republic Investment Management Inc.)最近提交給美國證券交易委員會的文件顯示，該公司第三季度增持了Ascendis Pharma A/S公司的股份17.3%。這位機構投資者在此期間又購買了2215股，之後又持有了15000股生物技術公司的股票。截至最近提交給美國證券交易委員會的文件，First Republic Investment Management Inc.持有的Ascendis Pharma A/S股份價值1,549,000美元。
A number of other institutional investors have also bought and sold shares of the business. Virtus ETF Advisers LLC increased its stake in Ascendis Pharma A/S by 4.9% in the 2nd quarter. Virtus ETF Advisers LLC now owns 2,856 shares of the biotechnology company's stock worth $265,000 after buying an additional 134 shares in the last quarter. Guggenheim Capital LLC increased its stake in Ascendis Pharma A/S by 7.2% in the 1st quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company's stock worth $236,000 after buying an additional 135 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Ascendis Pharma A/S by 14.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company's stock worth $264,000 after buying an additional 282 shares in the last quarter. US Bancorp DE grew its position in shares of Ascendis Pharma A/S by 29.2% during the third quarter. US Bancorp DE now owns 1,253 shares of the biotechnology company's stock valued at $130,000 after purchasing an additional 283 shares in the last quarter. Finally, Private Ocean LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $49,000.
其他一些機構投資者也買入和賣出了該公司的股票。Virtus ETF Advisers LLC在第二季度將其在Ascendis Pharma A/S的持股增加了4.9%。Virtus ETF Advisers LLC現在持有這家生物技術公司2,856股股票，價值265,000美元，上個季度又購買了134股。古根海姆資本有限責任公司在第一季度將其在Ascendis Pharma A/S的持股增加了7.2%。古根海姆資本有限責任公司(Guggenheim Capital LLC)現在持有這家生物技術公司2,008股股票，價值23.6萬美元，上個季度又購買了135股。Envestnet Asset Management Inc.在第一季度將其在Ascendis Pharma A/S的持股增加了14.4%。Envestnet Asset Management Inc.現在持有這家生物技術公司2,246股股票，價值26.4萬美元，該公司在上個季度又購買了282股。US Bancorp DE在第三季度將其在Ascendis Pharma A/S的股票頭寸增加了29.2%。US Bancorp DE現在擁有1253股這家生物技術公司的股票，價值13萬美元，此前在上個季度又購買了283股。最後，Private Ocean LLC在第三季度購買了價值約4.9萬美元的Ascendis Pharma A/S的新頭寸。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of research analysts have recently weighed in on ASND shares. The Goldman Sachs Group started coverage on Ascendis Pharma A/S in a research report on Thursday, October 20th. They set a "buy" rating and a $174.00 price objective for the company. Morgan Stanley increased their price target on shares of Ascendis Pharma A/S from $146.00 to $148.00 and gave the company an "overweight" rating in a report on Tuesday, November 15th. Oppenheimer increased their price target on shares of Ascendis Pharma A/S from $144.00 to $150.00 in a report on Thursday, November 3rd. SVB Leerink lowered their price target on shares of Ascendis Pharma A/S from $168.00 to $148.00 and set an "outperform" rating for the company in a report on Monday, November 14th. Finally, StockNews.com began coverage on shares of Ascendis Pharma A/S in a report on Wednesday, October 12th. They issued a "sell" rating for the company. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and a consensus target price of $160.27.
最近，許多研究分析師紛紛買入新日的股票。10月20日，星期四，高盛在一份研究報告中開始對Ascendis Pharma A/S進行報道。他們為該公司設定了“買入”評級和174.00美元的目標價。摩根士丹利在11月15日週二的一份報告中將Ascendis Pharma A/S的目標價從146.00美元上調至148.00美元，並給予該公司“增持”評級。在11月3日星期四的一份報告中，奧本海默將Ascendis Pharma A/S的目標股價從144.00美元上調至150.00美元。SVB Leerink在11月14日週一的一份報告中將Ascendis Pharma A/S的目標價從168.00美元下調至148.00美元，併為該公司設定了“跑贏大盤”的評級。最後，StockNews.com在10月12日星期三的一份報告中開始報道Ascendis Pharma A/S的股票。他們對該公司的評級為“賣出”。一位分析師對該股的評級為賣出，11位分析師對該公司的評級為買入。根據MarketBeat.com的數據，Ascendis Pharma A/S目前的平均評級為“中等買入”，共識目標價為160.27美元。
Ascendis Pharma A/S Stock Performance
Ascendis Pharma A/S股票表現
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($3.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.53). The business had revenue of $15.41 million for the quarter, compared to analysts' expectations of $10.67 million. Ascendis Pharma A/S had a negative net margin of 1,473.30% and a negative return on equity of 71.44%. As a group, equities analysts predict that Ascendis Pharma A/S will post -9.52 EPS for the current year.
Ascendis Pharma A/S(納斯達克：ASND-GET評級)最近一次發佈季度收益數據是在11月2日星期三。這家生物技術公司公佈了本季度每股收益(EPS)(3.05美元)，低於(2.52美元)和(0.53美元)的普遍預期。該業務當季營收為1,541萬美元，高於分析師預期的1,067萬美元。Ascendis Pharma A/S的淨利潤率為負1,473.30%，淨資產回報率為負71.44%。作為一個整體，股票分析師預測，Ascendis Pharma A/S本年度每股收益將達到9.52美元。
About Ascendis Pharma A/S
關於阿森迪斯醫藥A/S
(Get Rating)
(獲取評級)
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S是一家生物製藥公司，致力於候選藥物的開發。該公司專注於其Transconn技術，以創造前藥，提供可預測和持續釋放的未經修飾的母藥。該公司由Jan Moller Mikkelsen、Dirk Vetter和Harald Rau於2006年9月創立，總部設在丹麥的Hellerup。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Ascendis Pharma A/S (ASND)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 免費獲取StockNews.com關於Ascendis Pharma A/S的研究報告(ASND)
- Bed Bath&Beyond正在繞着排水溝走
- Allegro MicroSystems是一隻定位良好的半導體股票
- 斯科特奇蹟-Gro觸底，比賽逆轉
- 奧馳亞是一隻大衰退的股票，長期前景不確定
- Novavax的股價在1月份大幅上漲，而其他股票則出現下滑
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Get Rating).
想看看其他對衝基金持有什麼嗎？訪問HoldingsChannel.com獲取Ascendis Pharma A/S(納斯達克：ASND-GET評級)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ascendis Pharma A/S日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ascendis Pharma A/S和相關公司的最新新聞和分析師評級的每日簡要摘要。